TUESDAY, May 26 (HealthDay News) -- A new study affirms that the chemotherapy drug Abraxane is more effective, with less troublesome side effects, than the current drug of choice for metastatic breast cancer. When compared with Taxotere, Abraxane extended the time before a recurrence by almost seven months, effectively doubling survival. Both are members of a class of drugs known as taxanes.More »